GlassScriptPhysician profile
Spencer Fuller
NPI 1124513023
$5,938.19
in general payments reported to CMS, 2019-2025
14 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $124 · 2021: $708 · 2022: $3,232 · 2023: $567 · 2024: $362 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621 · Travel and Lodging: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.55 |
| Travel and Lodging | $150.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,502.49 | 2019-2023 | Total30, Dailies Total1, Precision 1 |
| Bausch & Lomb Americas INC. | $1,621.37 | 2022 | |
| Genentech USA, INC. | $637.62 | 2023-2025 | Vabysmo, Susvimo |
| Apellis Pharmaceuticals, INC. | $454.36 | 2024-2025 | Syfovre |
| Astellas Pharma US INC | $143.87 | 2023-2025 | Izervay |
| Eyepoint US, INC. | $127.58 | 2022-2023 | |
| Harrow Eye, LLC | $125.81 | 2025 | Triesence |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $115.98 | 2021 | |
| Aerie Pharmaceuticals, INC. | $50.00 | 2021 | |
| Genentech, INC. | $48.14 | 2025 | Susvimo |
| Neurotech Pharmaceuticals, INC. | $38.86 | 2025 | |
| Abbvie INC. | $32.10 | 2023 | |
| Ani Pharmaceuticals, INC. | $20.78 | 2025 | Iluvien |
| Sight Sciences, INC. | $19.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.